Part I: Vaccines for solid tumours (Q35937453)

11 August 2017

1 reference

title

Part I: Vaccines for solid tumours (English)

1 reference

11 August 2017

Simone Mocellin

1

1 reference

11 August 2017

Susanna Mandruzzato

2

1 reference

11 August 2017

Vincenzo Bronte

3

1 reference

11 August 2017

Mario Lise

4

1 reference

11 August 2017

Donato Nitti

5

1 reference

11 August 2017

1 November 2004

1 reference

Lancet Oncology Commission

11 August 2017

1 reference

11 August 2017

5

1 reference

11 August 2017

11

1 reference

11 August 2017

681-689

1 reference

A fresh look at tumor immunosurveillance and immunotherapy.

11 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

Antibodies against p53 are associated with poor prognosis of colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

Human tumor antigens recognized by T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

T-cell clones that react against autologous human tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

Post-transplant malignancy: the role of immunosuppression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

Vaccine therapy for malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

Autologous, hapten-modified vaccine as a treatment for human cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

Virus Augmentation of The Antigenicity of Tumor Cell

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

Glycoprotein glycosylation and cancer progression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

Tumor-specific shared antigenic peptides recognized by human T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

Recombinant viruses as a tool for therapeutic vaccination against human cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

Genetic vaccination: the advantages of going naked

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

CpG motifs in bacterial DNA and their immune effects

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

Immune network theory

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

Anti-idiotype vaccine against cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

Dendritic cell immunotherapy: mapping the way.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

Induction of Tumor-Specific Cytotoxic T Lymphocytes in Cancer Patients by Autologous Tumor RNA-Transfected Dendritic Cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

A new genetic method to generate and isolate small, short-lived but highly potent dendritic cell-tumor cell hybrid vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

Natural selection of tumor variants in the generation of "tumor escape" phenotypes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

CD4 T cells and their role in antitumor immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

Monoclonal antibody therapy for cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

The central role of CD4(+) T cells in the antitumor immune response

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

Cytokines and immune response in the tumor microenvironment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

Histamine in cancer immunotherapy: a preclinical background.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

Immortalized myeloid suppressor cells trigger apoptosis in antigen-activated T lymphocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

Tolerogenic dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

IDO and tolerance to tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

In vivo natural killer cell activities revealed by natural killer cell-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

The innate immune response to tumors and its role in the induction of T-cell immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

Induction of tumor-specific T cell memory by NK cell–mediated tumor rejection

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

Natural killer cells and dendritic cells: rendezvous in abused tissues

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

IL-12: a promising adjuvant for cancer vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

Priming of naive T cells inside tumors leads to eradication of established tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

Kinetics of cytokine expression in melanoma metastases classifies immune responsiveness

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

Dissecting tumor responsiveness to immunotherapy: the experience of peptide-based melanoma vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

Histamine dihydrochloride: inhibiting oxidants and synergising IL-2-mediated immune activation in the tumour microenvironment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

Cutting Edge: IL-10-producing CD4+ T cells mediate tumor rejection.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

Ex vivo identification, isolation and analysis of tumor-cytolytic T cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901610-9

7 January 2021

10.1016/S1470-2045(04)01610-9

Identifiers

DOI

1 reference

11 August 2017

1 reference